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Appendix A - Search terms used in the PROMOTION registry 
 
Bladder cancer RCTs 
("quality of life" OR “health related quality of life” OR "health status" OR “health outcomes” OR “patient 
outcomes” OR “depression” OR “anxiety” OR “emotional” OR “social” OR “psychosocial” OR 
“psychological” OR “distress” OR “social functioning” OR “social wellbeing” OR “patient reported 
symptom” OR "patient reported outcomes" OR pain OR fatigue OR “patient reported outcome” OR "PRO" 
OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR “symptom distress” OR “symptom burden” OR 
“symptom assessment” OR “functional status” OR sexual OR functioning) AND bladder 
 
Breast cancer RCTs 
("quality of life" OR “health related quality of life” OR "health status" OR “health outcomes” OR “patient 
outcomes” OR “depression” OR “anxiety” OR “emotional” OR “social” OR “psychosocial” OR 
“psychological” OR “distress” OR “social functioning” OR “social wellbeing” OR “patient reported 
symptom” OR "patient reported outcomes" OR pain OR fatigue OR “patient reported outcome” OR "PRO" 
OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR “symptom distress” OR “symptom burden” OR 
“symptom assessment” OR “functional status” OR sexual OR functioning OR “body image” OR “sexual”) 
AND (“breast” OR “breast cancer” OR “breast carcinoma” OR “breast tumour” OR “breast tumor”) 
 
Colorectal + anal cancers RCTs 
("quality of life" OR “health related quality of life” OR "health status" OR “health outcomes” OR “patient 
outcomes” OR “depression” OR “anxiety” OR “emotional” OR “social” OR “psychosocial” OR 
“psychological” OR “distress” OR “social functioning” OR “social wellbeing” OR “patient reported 
symptom” OR "patient reported outcomes" OR pain OR fatigue OR “patient reported outcome” OR "PRO" 
OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR “symptom distress” OR “symptom burden” OR 
“symptom assessment” OR “symptom distress” OR “functional status”) AND (colon OR colorectal OR 
rectum OR rectal OR “hepatic metastases” OR “liver metastases” OR “anal cancer”) 
 
Gynaecological cancers RCTs 
(gynecological OR GYN OR cervical OR ovarian OR endometrial OR vulvar OR vaginal OR uterine OR 
hysterectomy OR "fallopian tubes" OR clitoris OR vulva OR vulval OR vaginal OR endometrium OR ovary 
OR cervix OR uterus OR ovaries OR vagina OR pelvis OR “germ cell” OR genital OR “reproductive 
system” OR cervical OR "cone biopsy" OR conization OR oophorectomy OR vulvectomy) AND ("quality of 
life" OR "health related quality of life" OR "health status" OR "health outcomes" OR "patient outcomes" OR 
"depression" OR "anxiety" OR "emotional" OR "social" OR "psychosocial" OR "psychological" OR 
"distress" OR "social functioning" OR "social wellbeing" OR "patient reported symptom" OR "patient 
reported outcomes" OR pain OR fatigue OR "PRO" OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR 
"symptom distress" OR "symptom burden" OR "symptom assessment" OR "functional status" OR sexuality 
OR libido OR “body image” OR arousal OR orgasm OR “sexual desire” OR excitement OR vaginitis OR 
lubrication OR femininity OR appearance OR intimacy OR intercourse  OR relationship OR sexual OR 
bloating OR sex OR psychosexual OR sexuality OR dyspareunia OR “abdominal swelling” OR  constipation 
OR “vaginal bleeding” OR reconstructive OR “plastic surgery” OR reconstruction) AND (leiomyosarcoma 
OR sarcoma OR cancer OR malignant OR adenocarcinoma OR malignancy OR carcinoma OR neoplasm 
OR tumor OR tumour)  
Lung cancer RCTs 
("quality of life" OR “health related quality of life” OR "health status" OR “health outcomes” OR “patient 
outcomes” OR “depression” OR “anxiety” OR “emotional” OR “social” OR “psychosocial” OR 
“psychological” OR “distress” OR “social functioning” OR “social wellbeing” OR “patient reported 
symptom” OR "patient reported outcomes" OR “pain” OR “fatigue” OR “patient reported outcome” OR 
"PRO" OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR “symptom distress” OR “symptom burden” 
OR “symptom assessment” OR “functional status” OR “sexual” OR “functioning”) AND (“lung cancer” 
OR “lung carcinoma” OR “lung tum*” OR “lung” OR “non-small”) 
 
Prostate cancer RCTs 
("quality of life" OR “health related quality of life” OR "health status" OR “health outcomes” OR “patient 
outcomes” OR “depression” OR “anxiety” OR “emotional” OR “social” OR “psychosocial” OR 
“psychological” OR “distress” OR “social functioning” OR “social wellbeing” “patient reported symptom” 
OR "patient reported outcomes" OR pain OR fatigue OR “patient reported outcome” OR "PRO" OR "PROs" 
OR "HRQL" OR "QOL" OR "HRQOL" OR “symptom distress” OR “symptom burden” OR “symptom 
assessment” OR “functional status” OR sexual OR functioning) AND prostate 
   
Appendix B 
 
Classification of study endpoints* 
 
Study endpoint Classified as 
Overall survival Overall survival 
Progression-free survival 
Event-free survival 
Disease-free survival 
Time to progression 
Duration of response 
Progression-free survival 
Toxicity 
Safety 
Feasibility 
Maximum-tolerated dose 
Toxicity 
Response 
Efficacy 
Time to response 
Engraftment 
Time to failure 
Efficacy 
Health care utilization 
Health economics 
Healthcare utilization 
Laboratory parameters 
Genetic parameters 
Tumor biology 
Biological parameters 
Completion of planes treatment 
Achieved dose intenstity 
Compliance to treatment 
Completion of treatment 
 
 
*Based on classification performed by Hamaker et al. Ann Oncol 25:675-681, 2014. 
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